Is levodopa toxic?

Neurology

Volumn 47, Issue 6 SUPPL. 3, 1996, Pages

  Fahn, Stanley ^a,b  

^a Presbyterian Hospital ^*  (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE; LEVODOPA;

DEMENTIA; DISABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSKINESIA; HUMAN; MORTALITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0029775677     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_3.184s     Document Type: Review

References (154)

1. Fahn S. Adverse effects of levodopa in Parkinson's disease. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1989;88:385-409.
2. Fahn S, Calne DB. Considerations in the management of parkinsonism. Neurology 1978;28:5-7.
3. Fahn S, Barbeau A, Calne D, Markham C, Paulson G. Therapeutic controversies in movement disorders. Trans Am Neurol Assoc 1980;104:31-51.
4. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11:200-206.
5. Muenter MD. Should levodopa therapy be started early or late? Can J Neurol Sci 1984;11:195-199.
6. Caraceni T. A case for early levodopa treatment of Parkinson's disease. Clin Neuropharmacol 1994;17:S38-S42.
7. Quinn NP. A case against early levodopa treatment of Parkinson's disease. Clin Neuropharmacol 1994;17:S43-S49.
8. Yahr MD. Evaluation of long-term therapy in Parkinson's disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Editiones Roche, 1976;444-455.
9. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260.
10. Rajput AH, Stern W, Laverty WH. Chronic low dose levodopa therapy in Parkinson's disease: an argument for delaying L-dopa therapy. Neurology 1984;34:991-996.
11. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402-405.
12. Bergmann KJ, Mendoza MR, Yahr MD. Parkinson's disease and long-term L-dopa therapy. Adv Neurol 1986;45:463-467.
13. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986;36:1528-1530.
14. de Jong GJ, Meerwaldt JD, Schmitz PIM. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987;22:4-7.
15. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
16. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):6-12.
17. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10: 250-256.
18. Markham CH, Diamond SG. Evidence to support early levodopa therapy in PD. Neurology 1981;31:125-131.
19. Hoehn MMM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983;19(suppl):253-264.
20. Markham CH, Diamond SG. Modification of Parkinson's disease by long-term levodopa treatment. Arch Neurol 1986;43: 405-407.
21. Markham CH, Diamond SG. Long-term follow up of early dopa treatment in Parkinson's disease. Ann Neurol 1986;19: 365-372.
22. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson's mortality with early versus later dopa treatment. Ann Neurol 1987;22: 8-12.
23. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990;40:265-269.
24. Blin J, Bonnet A-M, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.
25. Roos RAC, Vredevoogd CB, van der Velde EA. Response fluctuations in Parkinson's disease. Neurology 1990;40:1344-1346.
26. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384.
27. Cedarbaum JM, Gandy SE, McDowell FH. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41:622-629.
28. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted county project. Neurology 1993;43:1918-1926.
29. Marttila RJ, Kuopio AM, Rinne UK. Survival in Parkinson's disease: early levodopa treatment enhances life expectancy [abstract]. New Trends Clin Neuropharm 1994;8:120-121.
30. Muenter MD, Tyce GM. L-Dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239.
31. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. Carnforth, England: Parthenon, 1992;89-112.
32. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1982;96-122.
33. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1982; 123-145.
34. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ('I-D-I' and 'D-I-D') in response to L-dopa therapy of Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
35. Tolosa ES, Martin WE, Cohen HP, Jacobson RL. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology 1975;25:177-183.
36. Shoulson I, Glaubiger GA, Chase TN. "On-off" response: clinical and biochemical correlations during oral and intravenous levodopa administration. Neurology 1975;25:1144-1148.
37. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22:535-540.
38. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
39. Sage JI, McHale DM, Sonsalla P, Vitagliano D, Heikkila RE. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology 1989;39:888-891.
40. Sage JI, Trooskin S, Sonsalla PK, Heikkila RE. Experience with continuous enteral levodopa infusions in the treatment of nine patients with advanced Parkinson's disease. Neurology 1989;39(suppl 2):60-63.
41. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
42. Fahn S. "On-off phenomenon with levodopa therapy in parkinsonism: clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 1974;24:431-441.
43. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24: 366-371.
44. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;4:372-378.
45. Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1988;24:363-365.
46. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989;39(suppl 2):11-19.
47. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;49:1123-1130.
48. Murata M, Kanazawa I. Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat. Neurosci Res 1993;16:15-23.
49. Bravi D, Mouradian MM, Roberts JW, Davis TL, Chase TN. End-of-dose dystonia in Parkinson's disease. Neurology 1993; 43:2130-2131.
50. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
51. Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57: 562-566.
52. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44:S15-S18.
53. Narabayashi H, Yokochi F, Nakajima Y. Levodopa-induced dyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry 1984;47:831-839.
54. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992;76:53-61.
55. Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995;45:753-761.
56. Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995;346:1383-1387.
57. Caparros-Lefebvre D, Blond S, Vermersch P, Pecheux N, Guieu JD, Petit H. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:268-273.
58. Limousin P, Pollak P, Benazzouz A, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995;10:672-674.
59. Limousin P, Pollak P, Hoffmann D, Benazzouz A, Perret JE, Benabid AT, Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients. Mov Disord 1996;11:231-235.
60. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992;327:1549-1555.
61. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994;35:172-180.
62. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995;38:379-388.
63. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124.
64. Paulson G. Practice parameters: initial therapy of Parkinson's disease (summary statement): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 1993;43:1296-1297.
65. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 1988;86:1398-1400.
66. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435.
67. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203.
68. Mena MA, Pardo B, Casarejos MJ, Fahn S, de Yebenes JG. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
69. Pardo B, Mena MA, Fahn S, de Yebenes JG. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284.
70. Mena MA, Pardo B, Paino CL, de Yebenes JG. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 1993;4:438-440.
71. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478.
72. Werner P, Mytilineou C, Cohen G, Yahr MD. Impaired oxidation of pyruvate in human embryonic fibroblasts after exposure to L-dopa. Eur J Pharmacol 1994;263:157-162.
73. Basma AN, Morris EJ, Nicklas WJ, Geller HM. L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 1995;64:825-832.
74. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95: 2458-2464.
75. Newcomer TA, Rosenberg PA, Aizenman E. Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin. J Neurochem 1995;64:1742-1748.
76. Newcomer TA, Rosenberg PA, Aizenman E. TOPA quinone, a kainate-like agonist and excitotoxin, is generated by a catecholaminergic cell line. J Neurosci 1995;15:3172-3177.
77. Pardo B, Mena MA, Casarejos MJ, Paino CL, de Yebenes JG. Toxic effects of L-dopa on mesencephalic cell cultures: protection with antioxidants. Brain Res 1995;682:133-143.
78. Mattammal MB, Haring JH, Chung HD, Raghu G, Strong R. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 1995;4:271-281.
79. Pardo B, Mena MA, de Yebenes JG. L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J Neurochem 1995;64:576-582.
80. Offen D, Ziv I, Gorodin S, Panet, H, Melamed E. Dopamine-melanin induces apoptosis in PC12 and neuronal cells: possible implications for therapeutic approaches in Parkinson's disease [abstract]. Mov Disord 1996;11(suppl 1):45.
81. Ziv I, Barzilai A, Offen D, Stein R, Achiron A, Melamed E. Dopamine-induced, genotoxic activation of programmed cell death: a role in nigrostriatal neuronal degeneration in Parkinson's disease? Adv Neurol 1996;69:229-233.
82. Mena MA, Casarejos MJ, Carazo A, Paino CL, De Yebenes JG. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-dopa toxicity. Neuroreport 1996;7: 441-445.
83. Han SK, Mytilineou C, Cohen G. L-Dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.
84. Yu PH, Lai CT, Boulton AA. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: selegiline may be toxic in presence of increased dopamine concentrations. BMJ 1996;312:703-704.
85. Steece-Collier K, Collier TJ, Sladek CD, Sladek JR. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990;110:201-208.
86. Yurek DM, Steece-Collier K, Collier TJ, Sladek JR. Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting. Exp Brain Res 1991;86:97-107.
87. Steece-Collier K, Yurek DM, Collier TJ, Junn FS, Sladek JR. The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing. Brain Res 1995;676: 404-408.
88. Zigmond MJ, Hastings TG, Abercrombie ED. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Ann NY Acad Sci 1992;648: 71-86.
89. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
90. Blunt S, Jenner P, Marsden CD. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts. Neuroscience 1991;40:453-464.
91. 3H] mazindol autoradiography. Neuroscience 1991; 43:95-110.
92. Blunt SB, Jenner P, Marsden CD. Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa. Exp Brain Res 1992;88:326-340.
93. Blunt SB, Jenner P, Marsden CD. Autoradiographic study of striatal D1-dopamine and D2-dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa. Brain Res 1992;582:299-311.
94. Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353: 246-250.
95. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723.
96. Przedborski S, Jackson-Lewis V, Fahn S. Antiparkinsonian therapies and brain mitochondrial complex I activity. Mov Disord 1995;10:312-317.
97. Cooper JM, Daniel SE, Marsden CD, Schapira AHV. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Mov Disord 1995;10:295-297.
98. Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995; 64:718-723.
99. Naudin B, Bonnet JJ, Costentin J. Acute L-dopa pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice. Brain Res 1995; 701:151-157.
100. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995;64:919-924.
101. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem 1995;64:1645-1654.
102. Maruyama W, Dostert P, Naoi M. Dopamine-derived 1-methyl-6,7-dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: in vivo and in vitro studies. J Neurochem 1995;64:2635-2643.
103. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 1996;93:1956-1961.
104. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12:1658-1667.
105. Nakao N, Frodl EM, Widner H, et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Med 1995;1:226-231.
106. Spencer JPE, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-dopa and dopamine: relevance to Parkinson's disease. Neuroreport 1995;6:1480-1484.
107. Cotzias GC, Miller ST, Tang LC, Papavasiliou PS. Levodopa, fertility, and longevity. Science 1977;196:549-551.
108. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
109. Reches A, Fahn S. Chronic dopa feeding of mice. Neurology 1982;32:684-685.
110. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopamine neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43: 990-993.
111. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
112. Li CL, Werner P, Cohen G. Lipid peroxidation in brain: interactions of L-dopa/dopamine with ascorbate and iron. Neurodegeneration 1995;4:147-153.
113. Spencer JPE, Jenner A, Butler J, et al. Evaluation of the pro-oxidant and antioxidant actions of L-dopa and dopamine in vitro: implications for Parkinson's disease. Free Radical Res 1996;24:95-105.
114. Rajput AH, Fenton ME, Dhand A. Is levodopa toxic to nondegenerating substantia nigra cells? Clinical evidence [abstract]. Neurology 1996;46:A371.
115. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal. Mov Disord 1994;9: 125-138.
116. Graham DG, Tiffamy SM, Bell WR, Gutknecht WF. Autooxidation versus covalent binding of quinone as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653.
117. Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in parkinson's disease and incidental Lewy body disease. Ann Neurol 1992; 32:S82-S87.
118. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 1993;87:6-13.
119. Hornykiewicz O. Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects. In: Costa E, Côté LJ, Yahr MD, eds. Biochemistry and pharmacology of the basal ganglia. Hewlett, NY: Raven, 1966:171-185.
120. Calne DB, Stern GM, Laurence DR, Sharkey J, Armitage P. L-Dopa in postencephalitic parkinsonism. Lancet 1969;1: 744-746.
121. Sacks OW, Kohl M, Schwartz W, Messeloff C. Side-effects of L-dopa in postencephalitic parkinsonism. Lancet 1970;1: 1006.
122. Duvoisin RC, Lobo-Antunes J, Yahr MD. Response of patients with postencephalitic parkinsonism to levodopa. J Neurol Neurosurg Psychiatry 1972;35:487-495.
123. Sacks OW. Awakenings. Garden City, NY: Doubleday, 1974.
124. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
125. Langston JW, Ballard PA. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: implications for treatment and the pathophysiology of Parkinson's disease. Can J Neurosci 1984;11:160-165.
126. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
127. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20:415-455.
128. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979;1:249-254.
129. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
130. Langston JW, Forno LS, Rebert CS, Irwin I. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes selective damage to the zona compacta of the substantia nigra in the squirrel monkey. Brain Res 1984;292:390-394.
131. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49:492-497.
132. Hietanen M, Teravainen H. The effect of age of disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:244-249.
133. Stern Y, Marder K, Tang MX, Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993;43:1690-1692.
134. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43: 2227-2229.
135. Cohen G. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm 1983;(suppl 19):89-103.
136. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol 1986;45:119-125.
137. Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann NY Acad Sci 1989;570:186-196.
138. Fornstedt B, Pileblad E, Carlsson A. In vivo autoxidation of dopamine in guinea pig striatum increases with age. J Neurochem 1990;55:655-659.
139. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(suppl 3):32-37.
140. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32:S2-S9.
141. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand 1991;84:6-15.
142. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
143. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32: 804-812.
144. Beckman JS, Chen J, Crow JP, Ye YZ. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 1994;103:371-380.
145. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366.
146. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990;170: 1049-1055.
147. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982; 33:305-310.
148. Perry TL, Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986;67:269-274.
149. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
150. Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992;32:799-803.
151. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-442.
152. Rajput AH, Uitti RJ, Ho M, Offord K, Rajput A, Basran P. Current survival profile in parkinsonism [abstract]. New Trends Clin Neuropharmacol 1994;8:121-122.
153. Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 1992;43:357-363.
154. Louis ED, Marder K, Cote L, Tang M-X, Mayeux R. Age at death is significantly younger in patients with Parkinson's disease who have dementia and severe extrapyramidal signs [abstract]. Neurology 1996;46:A377.